- Home
- ATAI vs TSHA Comparison
ATAI vs TSHA Comparison
Compare ATAI & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- TSHA
- Stock Information
- Founded
- ATAI 2018
- TSHA 2019
- Country
- ATAI Germany
- TSHA United States
- Employees
- ATAI N/A
- TSHA N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- TSHA Health Care
- Exchange
- ATAI Nasdaq
- TSHA Nasdaq
- Market Cap
- ATAI 282.6M
- TSHA 262.4M
- IPO Year
- ATAI 2021
- TSHA 2020
- Fundamental
- Price
- ATAI $1.46
- TSHA $1.75
- Analyst Decision
- ATAI Strong Buy
- TSHA Strong Buy
- Analyst Count
- ATAI 3
- TSHA 8
- Target Price
- ATAI $10.50
- TSHA $6.63
- AVG Volume (30 Days)
- ATAI 1.8M
- TSHA 2.4M
- Earning Date
- ATAI 05-14-2025
- TSHA 05-13-2025
- Dividend Yield
- ATAI N/A
- TSHA N/A
- EPS Growth
- ATAI N/A
- TSHA N/A
- EPS
- ATAI N/A
- TSHA N/A
- Revenue
- ATAI $308,000.00
- TSHA $8,333,000.00
- Revenue This Year
- ATAI $65.58
- TSHA N/A
- Revenue Next Year
- ATAI N/A
- TSHA N/A
- P/E Ratio
- ATAI N/A
- TSHA N/A
- Revenue Growth
- ATAI N/A
- TSHA N/A
- 52 Week Low
- ATAI $1.03
- TSHA $1.05
- 52 Week High
- ATAI $2.57
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- ATAI 52.18
- TSHA 58.14
- Support Level
- ATAI $1.41
- TSHA $1.13
- Resistance Level
- ATAI $1.51
- TSHA $1.36
- Average True Range (ATR)
- ATAI 0.12
- TSHA 0.14
- MACD
- ATAI 0.03
- TSHA 0.03
- Stochastic Oscillator
- ATAI 87.50
- TSHA 100.00
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.